LYT-100 in Post-acute COVID-19 Respiratory Disease

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Covid19, Post-acute COVID-19 Respiratory Disease

In brief

This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.

Key facts

Study ID
NCT04652518
Run by
PureTech
People needed
185
Starts
2020-12-11
Expected to finish
2022-07-18
Last updated by the study team
2026-06-23

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.